Ergomed plc Ergomed's PrimeVigilance hosts automation seminar

TIDMERGO

Ergomed plc

04 December 2017

PRESS RELEASE

Ergomed's PrimeVigilance hosts prestigious intelligent automation seminar for the International Society of Pharmacovigilance

- PrimeVigilance hosting Intelligent Automation in Pharmacovigilance seminar in Cambridge, MA, 4-5 December

   -     Jan Petracek, CEO of PrimeVigilance, presenting The optimal service mix for 2020 

London, UK - 4 December 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces that its pharmacovigilance subsidiary PrimeVigilance will be organising and presenting at the International Society of Pharmacovigilance's Intelligent Automation in Pharmacovigilance seminar to be held at Biogen's headquarters in Cambridge, MA, from 4-5 December 2017.

Reacting to the question: "can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?", this seminar is the first of its kind worldwide to cover this complex development area. Over 30 speakers from the most influential companies in pharmacovigilance automation will present their state of the art technologies and examine the disruption expected within the industry. Participating bodies include: AstraZeneca, Bayer, Biogen, Celgene, Genentech, Takeda and the FDA and the MHRA.

PrimeVigilance's CEO, Jan Petracek, will be presenting the results from its successful pilot project demonstrating how robotic process automation of selected pharmacovigilance systems can increase efficiency by up to 400 times, increasing speed, reducing cost and improving accuracy. PrimeVigilance is working on the early deployment of robots in its operations. By investing in technology and people, PrimeVigilance has achieved organic growth of around 50% per year over the last few years and has, in addition, successfully incorporated acquired companies. PrimeVigilance aims to be the global leader in pharmacovigilance by 2020.

Dr Jan Petracek, CEO of PrimeVigilance, said: "PrimeVigilance has consistently demonstrated growth which is in no small part due to our market-leading adoption of new techniques and technologies and we are at the forefront of robotic automation, the next leap forward in technology for our industry. We look forward to discussing these advances in pharmacovigilance automation and how they can increase efficiency and accuracy. Pharmacovigilance is an extremely fast-growing and highly regulated market and we are pleased to be able to share our views on meeting these increasingly complex regulatory requirements."

For more information on the seminar and to view the full programme, please visit: http://isoponline.org/training/isop-seminar.

ENDS

Enquiries:

 
 Ergomed plc / PrimeVigilance                            Tel: +44 (0) 
  Limited                                                 1483 503205 
 Jan Petracek (CEO of PrimeVigilance) 
 
 
 Numis Securities Limited                                Tel: +44 (0) 
                                                         20 7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                              Tel: +44 (0) 
                                                         20 7496 3000 
 Alex Price (Joint Broker) 
 
 Consilium Strategic Communications                      Tel: +44 (0) 
  - for UK enquiries                                     20 3709 5700 
 Chris Gardner / Mary-Jane                [e-mail] 
  Elliott 
  Ivar Milligan / Philippa Gardner 
 
 MC Services - for Continental                           Tel: +49 211 
  European enquiries                                        5292 5222 
 Anne Hennecke 
 
 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRATJBBTMBBMTLR

(END) Dow Jones Newswires

December 04, 2017 02:00 ET (07:00 GMT)